 |
|
Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
Ji Young Park, Seung Hun Jang, Chang Youl Lee, Taehee Kim, Soo Jie Chung, Ye Jin Lee, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung
Tuberc Respir Dis. 2022;85(2):155-164. Published online 2022 Jan 20 DOI: https://doi.org/10.4046/trd.2021.0139
|
|
Citations to this article as recorded by
 The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Alessandra Ferro, Gian Marco Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno
Critical Reviews in Oncology/Hematology.2024; 196: 104295. CrossRef New Targeted Therapy for Non-Small Cell Lung Cancer
Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee
Tuberculosis and Respiratory Diseases.2023; 86(1): 1. CrossRef The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
Kuan-Chih Chen, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
OncoTargets and Therapy.2023; Volume 16: 317. CrossRef Prognostic Significance of Pretreatment Plasma D-dimer Levels in EGFR-Positive Advanced Non-Small Cell Lung Cancer Patients Receiving Osimertinib: A Multicentre Retrospective Study
Qianfei Liu, Liping Tan, Jianbo He, Ruiling Ning, Aiping Zeng, Yilin Chen
International Journal of General Medicine.2023; Volume 16: 5481. CrossRef MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
Richard E. Kast, Alex Alfieri, Hazem I. Assi, Terry C. Burns, Ashraf M. Elyamany, Maria Gonzalez-Cao, Georg Karpel-Massler, Christine Marosi, Michael E. Salacz, Iacopo Sardi, Pieter Van Vlierberghe, Mohamed S. Zaghloul, Marc-Eric Halatsch
Cancers.2022; 14(10): 2563. CrossRef
|